Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates

Item Type:

Hyperlink

Title

Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates

Subject

Description

The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) as part of the emergency response to an ongoing Ebola outbreak in the North Kivu and Ituri Provinces.

Creator

Date Last Updated (Year-Month-Day)

2019-08-12